IP Library Granted Patent US 12702713
Granted Patent B2
US 12702713 · App. 17/272,144 · Granted Aug 11, 2026

Semi-solid, oil-based pharmaceutical compositions containing pirfenidone for application in tissue repair

Inventors: Juan Armendáriz Borunda (Mexico City, MX); José Agustín Rogelio Magaña Castro (Mexico City, MX); Laura Vázquez Cervantes (Mexico City, MX)
Assignee: Excalibur Pharmaceuticals, Inc.
A61K47/10A61K8/4973A61K9/0014A61K9/06A61K31/4418A61K47/18A61K47/26A61K47/32A61Q19/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12702713
App. No.
17/272,144
Granted
Aug 11, 2026
Kind
B2
Abstract

The present invention describes semi-solid pharmaceutical compositions containing Pirfenidone, which offer advantages over other cutaneously administered pharmaceutical forms known in the prior art, due to its permeability and absorption characteristics, which are useful in the treatment for restoring tissues that have suffered loss or degradation of extracellular matrix resulting in the formation of wrinkles or skin thinning.

Claims (42)

1 . A semi-solid pirfenidone pharmaceutical composition comprising:

(a) from 2% to 12% w/w pirfenidone;

(b) from 20% to 60% w/w of propylene glycol;

(c) from 5% to 10% w/w total of one or more of sorbitan stearate, ceteareth-6 and stearyl alcohol, ceteareth-25, and polysorbate 60;

(d) from 2% to 8% w/w total of one or more of cetyl alcohol and stearyl alcohol;

(e) from 0.5% to 3% w/w of one or more dimethicone;

(f) from 0.1% to 2% w/w of sodium methylparaben;

(g) from 0.05% to 0.2% w/w of carbomer;

(h) from 0.05% to 0.2% w/w of triethanolamine;

(i) from 0.05% to 0.2% w/w of sodium propylparaben; and

(j) from 0.0005% to 0.003% w/w of citric acid;

wherein the semi-solid pharmaceutical composition is in the form of a cream.

2 . The semi-solid pirfenidone pharmaceutical composition according to claim 1 , wherein the composition comprises:

(a) from 2% to 12% w/w Pirfenidone;

(b) 50% w/w Propylene Glycol;

(c) 6.382% w/w sorbitan stearate;

(d) 2% w/w Cetyl Alcohol;

(e) 2% w/w Stearyl alcohol;

(f) 1% w/w ceteareth-6 and stearyl alcohol;

(g) 1% w/w ceteareth-25;

(h) 1% w/w Dimethicone;

(i) 0.617% w/w polysorbate 60;

(j) 0.147% w/w Sodium Methylparaben;

(k) 0.1% w/w Carbomer;

(l) 0.1% w/w_Triethanolamine;

(m) 0.066% w/w Sodium Propylparaben;

(n) 0.001% w/w Citric acid; and

(o) Water qs 100%.

3 . The semi-solid pirfenidone pharmaceutical composition of claim 1 further comprising from 0.008% to 0.8% of an antiseptic/preservative.

4 . A method of manufacturing the semi-solid pirfenidone pharmaceutical composition according to claim 1 , the method comprising:

(1) Stirring sorbitan stearate, Cetyl Alcohol, Stearyl Alcohol, ceteareth-6 and stearyl alcohol, ceteareth-25, and Dimethicone and heating at 75-80° C.;

(2) Adding carbomer to 30% of the total water in the composition;

(3) Heating propylene glycol to 75-80° C. and stirring, before gradually adding Pirfenidone while stirring constantly and heating at 75-80° C.;

(4) Maintaining stirring and heating of the reaction of step 3 for 30 min;

(5) Gradually adding Sodium Methylparaben, Sodium Propylparaben, Citric Acid, and Tween 60 (Polysorbate 60 to 30% of the total water in the composition while stirring constantly until completely dissolved;

(6) Gradually adding the contents of step 2 and step 5 to the solution of step 4 while stirring constantly and maintaining heating at 75-80° C.;

(7) Adding the mixture of step 6 to the mixture of step 1 while stirring at 75-80° C. and then maintaining stirring for 20 minutes and lowering the mixture temperature to 40-45° C.;

(8) Gradually adding triethanolamine to the remaining 60% of the total water in the composition while stirring constantly until completely dissolved; and

(9) Adding the solution of step 8 to the mixture of step 7 while stirring for 60 minutes or until reaching a temperature of 30-35° C.

5 . A method of restoring skin imperfections caused by the loss of collagen and other extracellular matrix proteins, the method comprising administering the semi-solid pirfenidone pharmaceutical composition according to claim 1 to the skin of an individual in need of said treatment.

6 . The method of claim 5 , wherein the extracellular matrix proteins are fibronectin and elastin.

7 . A method of treating wrinkles and/or skin thinning comprising administering the semi-solid pirfenidone pharmaceutical composition of claim 1 to the skin of an individual in need of said treatment.